Baptist Memorial Health Care/Mid South NCORP Minority Underserved Consortium

浸信会医疗保健/中南部服务不足的NCORP是浸信会纪念的一部分 医疗保健公司(BMHCC)，一个基于信仰的非营利性医疗系统，拥有22家医院，21家 门诊肿瘤科诊所，8个放射设施，19个门诊输液中心，为 每年大约有8000名新的癌症患者。北京医疗中心的服务范围覆盖111个县，430万个 人民。这是三角洲地区管理局252个县和教区的44%，国会 被公认为美国最贫困的人口。在这个种族上，BMHCC提供了25%的癌症护理， 社会经济和文化多样化的地区，那里有一些最高的癌症和 美国最脆弱的公共卫生基础设施。在我们的NCORP之前，这些患者无法进入临床 审判。自2014年8月我们的NCORP开始以来的4年里，每年有90多名患者被 登记参加试验，包括2017/18年度的168名患者；我们登记的患者中39%是少数族裔，17% 居住在农村地区，13%没有保险，21%有医疗补助。我们的NCORP成员服务于多个 NCORP工作组和NCI指导委员会，包括癌症预防指导委员会。我们 利用我们独特的专业知识，在乳房、胸科、 胃肠道和血液肿瘤学将开发疾病特异性研究小组，将我们的 NCORP研究与我们的临床肿瘤护理计划密切相关。这一战略加快了我们在 过去两年。我们在全系统范围内实施的电子健康记录系统EPIC已经 增强了我们的研究能力，特别是在癌症护理提供研究方面。对于新的筹资周期，我们 建议将我们的NCORP研究基础设施扩展到BMCC的全部范围，并特别强调 在密西西比州增加病人招募。使用实施和团队科学 原则和数据驱动的方法，我们的首要目标是增加BMHCC肿瘤学的比例 参与临床试验的患者比例从2018年的3%上升到2025年的10%。每年有近8000个新的 癌症病例，这将大大超过NCORP的最低要求，对我们的 患者、社区和医疗系统，因为我们相信，最好的治疗方法是临床试验。 我们的具体目标是增加：1.到2025年，活跃站点的数量将从5个增加到16个，扩展到我们所有的 密西西比州的机构；2)肿瘤学相关提供者将患者增加到&gt；90%的比例；3)临床试验 在泌尿生殖和妇科肿瘤学方面的活动；年平均患者登记参加NCORP试验从 90到&gt；250。实现我们的目标将有助于实现NCI改善这个关键美国人的健康的使命 通过缩小一个公认的重大健康差距来缩小人口结构：大量贫困人口获得机会较少， 密西西比河三角洲地区的少数民族和农村人口获得高质量的肿瘤治疗。

The Baptist Memorial Health Care/Mid-South Minority Underserved NCORP is part of Baptist Memorial Healthcare Corporation (BMHCC), a non-for-profit faith-based healthcare system with 22 hospitals, 21 outpatient oncology clinics, 8 radiation facilities, and 19 outpatient infusion centers, providing care for approximately 8000 new cancer patients each year. BMHCC’s service area covers 111 counties, 4.3 million people. This is 44% of the 252 counties and parishes in the Delta Regional Authority, congressionally acknowledged as the most indigent population in the US. BMHCC provides 25% of cancer care in this racially, socioeconomically and culturally diverse region, which has some of the highest volumes of cancer and the most fragile public health infrastructure in the US. Before our NCORP, these patients had no access to clinical trials. In the 4 years since our NCORP began in August 2014, more than 90 patients per year have been enrolled into trials, including 168 patients in 2017/18; 39% of our enrolled patients are racial minorities, 17% reside in rural areas, 13% are uninsured, 21% have Medicaid. Members of our NCORP serve on multiple NCORP taskforces and NCI Steering Committees, including the Cancer Prevention Steering Committee. We have used our unique expertise in establishing Multidisciplinary Care Delivery programs in Breast, Thoracic, Gastrointestinal and Hematologic Oncology to develop Disease-Specific Research Groups that link our NCORP research closely to our clinical oncology care programs. This strategy has accelerated our progress in the past 2 years. Our system-wide implementation of the Electronic Health Record system, EPIC, has enhanced our research ability, especially in Cancer Care Delivery Research. For the new funding cycle, we propose to expand our NCORP research infrastructure across the full extent of BMHCC, with special emphasis on increasing patient recruitment across the state of Mississippi. Using Implementation and Team Science principles and a data-driven approach, our overarching goal is to increase the proportion of BMHCC oncology patients who participate in clinical trials from <3% in 2018 to 10% by 2025. With almost 8000 annual new cancer cases, this would significantly exceed the minimum requirements of the NCORP, to the benefit of our patients, communities and healthcare system, because we believe that ‘the best treatment is a clinical trial.’ Our specific aims are to increase the: 1.) number of active sites from 5 to 16 by 2025, by expanding to all our Mississippi institutions; 2.) proportion of oncology-related providers accruing patients to >90%; 3.) clinical trials activity in urogenital and gynecologic oncology; 4.) average annual patient-enrollment into NCORP trials from 90 to >250. Achieving our goal will help achieve the NCI’s mission of improving the health of this key US population demographic by narrowing a major recognized health disparity: poor access of the large indigent, racial minority and rural populations within the Mississippi Delta region to high quality oncologic care.